Research in ContextEvidence Before this StudyOn July 18, 2018, we searched PubMed with the terms "*mcr-3* and China \[21 from local epidemiology\]", "MCR-3 and function \[1 references\]", "MCR-3 and evolution \[no references\]", for reports published between January 2000 and July 2018. We did not restrict our search by language of publication. Our search identified some group reported the sporadic cases of MCR-3 in very confined area and very limited in number in China. Evidently, comprehensive epidemiology of MCR-3 remains unclear in China. More importantly, we found no reports addressing mechanisms of MCR-3 action. Therefore, it is very necessary to elucidate its potential spread, evolution and functional aspects of MCR-3 polymyxin resistance.Added Value of this StudyOur results represent a first multi-province study on the dissemination of MCR-3 in China. Also, we report the origin and possible evolution of MCR-3. We have integrated multiple approaches to systematically address the biochemical mechanism and physiological roles of MCR-3 action.Implications of all the Available EvidenceOur data shows that 49(49/6497 = 0.75%) isolates from 13 provinces in China, comprising 40 samples (40/4144 = 0.97%) from 2017 and 9 samples (9/2353 = 0.38) from 2016, were *mcr-3* positive. This study suggests that the threat of *mcr-3* to public health should be assessed because of the potential prevalence of *mcr-3*. In addition, given that the resistance mechanism of MCR-3 is similar to *mcr-1*, we suggest that further studies are needed to clarify the evolutionary pattern of *mcr-3*.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Antimicrobial resistance (AMR) has become a global public health priority. The accelerated development of multidrug resistance (MDR) is attributed in part (if not completely) to the massive and inappropriate use of antimicrobials in agricultural and clinical settings. Human infections caused by MDR pathogens result in over 70,000 deaths in the United States each year \[[@bb0005], [@bb0010]\]. In fact, a team led by Prof. Lord Jim O\'Neil has estimated that AMR could result in 10 million deaths a year worldwide by 2050 \[[@bb0015]\]. Although the accuracy of this frightening prediction is uncertain, we acknowledge the enormous burden AMR causes at multiple levels (economic, social, clinical and public health) \[[@bb0020]\]. This highlights the importance and urgency of a coordinated international action to prevent and control the worldwide spread of AMR \[[@bb0020], [@bb0025]\].

Polymyxins refer to an array of non-ribosomally-synthesized, [c]{.ul}ationic [a]{.ul}nti[m]{.ul}icrobial cyclic-[p]{.ul}eptides (CAMP) \[[@bb0030]\]. Among the five known subtypes, polymyxin B and polymyxin E (Colistin) are extensively used in agricultural production and clinical therapies \[[@bb0030], [@bb0035], [@bb0040]\]. Historically, the primary target of colistin is thought to be the negatively charged lipid A moiety of lipopolysaccharides (LPS) on the outer-leaflet of the bacterial outer membrane \[[@bb0045]\]. Despite its potential nephrotoxicity and neurotoxicity \[[@bb0030], [@bb0050], [@bb0055], [@bb0060]\], colistin is still used for treatment as an ultimate line of defense against critical infections caused by MDR pathogens (esp. carbapenemase-producing *Enterobacteriaceae*) \[[@bb0035], [@bb0065], [@bb0070]\]. However, an acquired resistance to polymyxin has been frequently found in certain species of bacterial pathogens like *Klebsiella pneumoniae* (*K. pneumoniae*) \[[@bb0075]\] and *Salmonella enterica* (*S. enterica*) \[[@bb0080], [@bb0085]\]. The chemical mechanism underlying the colistin resistance consistently involves bacterial lipid A-centered surface remodeling, including i) The addition of 4-amino-4-deoxy-L-arabinose in *S*. *enterica* \[[@bb0080], [@bb0085]\] and *Pseudomonas aeruginosa* \[[@bb0090]\]; ii) The attachment of [p]{.ul}hospho[e]{.ul}thanol[a]{.ul}mine (PEA) in *Neisseria* \[[@bb0095]\], *Acinetobacter baumannii* \[[@bb0100]\] and *Campylobacter jejuni* \[[@bb0105]\]; and iii) Glycine/diglycine modification in the pandemic *Vibrio cholerae* biotype EI Tor \[[@bb0110], [@bb0115], [@bb0120], [@bb0125]\]. Intrinsic resistance to polymyxin is limited to the originally-resistant population. However, the recent emergence and global discovery of plasmid-borne [m]{.ul}obilized [c]{.ul}olistin [r]{.ul}esistance determinants (*mcr-1*) potentially threatens the clinical effectiveness of colistin as a last-resort antibiotic against carbapenem-resistant superbugs \[[@bb0130]\].

The *mcr-1* gene product, MCR-1, is a PEA lipid A transferase, belonging to the "YhjW/YjdB/YijP" alkaline phosphatase super-family \[[@bb0130], [@bb0135]\]. MCR-1 catalyzes the transfer of the PEA group from its physiological donor [p]{.ul}hosphatidyl[e]{.ul}thanolamine (PE) to the 1(4′)-phosphate position of lipid A glucosamine (GlcN) moieties \[[@bb0095], [@bb0140], [@bb0145]\]. Structure-guided functional studies have determined this mechanism and demonstrated that the enzymatic activity of MCR-1 renders the recipient strains resistant to polymyxin \[[@bb0135], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0175]\]. Intriguingly, the determinants of transferable colistin resistance have extended beyond MCR-1, to a number of new MCR-like members \[[@bb0180]\] (namely MCR-2 \[[@bb0185], [@bb0190], [@bb0195]\], MCR-3 \[[@bb0200]\], MCR-4 \[[@bb0205]\], MCR-5 \[[@bb0210]\], MCR-6 \[Genbank no.: [ASK49942](ncbi-p:ASK49942){#ir0005}\] (Indeed, it is a MCR-1/2 progenitor from *Moraxella* sp. MSG47-C17 \[[@bb0215]\], and exhibits high level of homology to ICR-Mo of *M. osloensis* \[[@bb0220]\]. Thus, it is supposed to be renamed as ICR-M), MCR-7 \[[@bb0225]\] and MCR-8 \[[@bb0230]\]), as well as over a dozen of new heterogeneous MCR-1 variants (e.g., MCR-1.2 \[[@bb0235]\] and MCR-1.6 \[[@bb0240]\]). Unlike the predominant MCR-1 which is distributed world-wide \[[@bb0245]\], both MCR-2 (81% identity to MCR-1 and originally found in Belgium \[[@bb0185], [@bb0190]\], and very recently detected in pigs/poultries \[[@bb0195]\] and human vaginal swabs \[[@bb0250]\] from China) and MCR-5 (only detected in Germany \[[@bb0210]\]) are thought to be two rare members of the MCR-like protein family. This is slowly changing with the discovery of MCR-2 and its variants in countries like China \[[@bb0195]\]. As for MCR-4, it has been detected in a pig isolate of *S. enterica* in Italy 2013 \[[@bb0205]\], swine isolates of *E. coli* from Spain and Belgium in 2015--2016 \[[@bb0205]\], and clinical isolates of carbapenemase-producing *Enterobacter cloacae* from Singapore in 2017 \[[@bb0255]\]. In terms of epidemiological/geographic distribution, MCR-3 seems to be second only to MCR-1. Phylogenetic analysis indicates that MCR-3 is evolutionarily distinct from MCR-1 and closely clustered with chromosomally-encoded MCR-like proteins in certain species of *Aeromonas* ([Fig. 3](#f0015){ref-type="fig"}) \[[@bb0260], [@bb0265]\]. To the best of our knowledge, the new *mcr-3* gene has been discovered in 3 of 7 continents, namely Asia (China \[[@bb0200], [@bb0270]\], Singapore \[[@bb0255]\], Japan \[[@bb0275]\], Thailand \[[@bb0200]\] and Malaysia \[[@bb0200]\]), Europe (Denmark \[[@bb0280], [@bb0285]\], France \[[@bb0290]\] and Spain \[[@bb0295]\]) and North America (the United States \[[@bb0200]\]). Given that i) In Europe, colistin is used to treat bacterial infections of livestock (such as pigs, cows, and goats) \[[@bb0300]\]; and ii) Colistin is heavily supplemented as a growth promoter of livestock (pigs and poultries) in Asian countries (e.g., China, Japan, and Vietnam) \[[@bb0305]\], it is possible that indiscriminate antibiotic use has selected for the emergence of new colistin resistance determinants like *mcr-3*.

In fact, the growing body of *mcr-3* variants includes *mcr-3.2* \[D295E\] \[[@bb0200]\], *mcr-3.3* \[G373V\] \[[@bb0200]\], *mcr-3.4* \[M23V\], *mcr-3.5* \[T488I\] \[[@bb0285], [@bb0290]\], and *mcr-3.7* \[M23V, A457E, T488I\] \[[@bb0270]\]. Most of them are located on IncHI2-type plasmids, like pWJ-1 (\~260 kb), IncP-like plasmid (\~50 kb), F46: A-: B20 IncF plasmid \[[@bb0290]\], respectively. The range of *mcr-3*-harboring host bacteria includes *E. coli* \[[@bb0200], [@bb0270], [@bb0285], [@bb0290], [@bb0295]\], *K. pneumoniae* \[[@bb0200]\] and *S.typhimurium* \[[@bb0200], [@bb0280]\]. Of note, *mcr-3*-bearing bacteria in Europe are frequently prevalent in either human infections \[[@bb0200], [@bb0280]\] (even bloodstream infections \[[@bb0285]\]) or epidemic MDR lineages of *E. coli* (ST744 \[[@bb0290]\] and ST131 \[[@bb0285]\]). To our surprise, *mcr-3* has been found to coexist with *mcr-1* \[[@bb0280], [@bb0295]\] (or *mcr-4* \[[@bb0255]\]) in a single cell, in MDR pathogens \[[@bb0280], [@bb0295]\] and even in *bla*~NDM5~-harboring superbugs \[[@bb0270]\]. This suggests an urgent need to introduce *mcr-3* into national surveillance programs for monitoring of antibiotic resistance. Although two independent research groups recently evaluated the prevalence and clinical risk of *mcr-1* carriage in human infections \[[@bb0310], [@bb0315]\], the molecular epidemiology and functional aspects of *mcr-3* in China are poorly understood. In this work, we aim to close this knowledge gap and present an overview of the dissemination, comparative genomics, evolution and mechanism of MCR-3-mediated colistin resistance.

2. Methods {#s0025}
==========

2.1. Ethics and Consents {#s0030}
------------------------

Ethical approval was sought and informed consent was provided by patients, healthy volunteers and farm owners. Individual consent forms were translated into Mandarin Chinese and the study vocally explained to each subject. All documents complete with patient signatures have been retained. All participants held the right to withdraw from the study at any stage.

2.2. Epidemiological Study {#s0035}
--------------------------

We undertook a retrospective cross-sectional study to assess the prevalence of *mcr-3*-carrying isolates in animal, farmer, inpatient and healthy volunteer in China. A total of 6497 non-duplicate fecal samples were collected from thirteen provinces in China, from Oct. 2016 to Dec. 2017. Specifically, 1951 fecal samples of animal were collected from 32 swine farms in 13 provinces, and the 174 fecal samples of farmer who approved and provided consent forms were collected from 16 farms in 9 provinces ([Tables 1](#t0005){ref-type="table"} and S1). The 2281 inpatients submitting fecal specimens during the study timeframe to the hospital microbiology laboratories for diagnostic purposes were asked to participate in the study by means of an invitation included with the diagnostic test report returned to the patient. The 2091 healthy volunteers were including who came into the hospitals for routine physical examinations. Fecal samples from inpatient and healthy volunteers were recovered from 5 hospitals which contain \>6000 beds in Guangdong province. All these samples were isolated from Oct. 2016 to Dec. 2017 (Tables S1 and S2).Table 1Prevalence of *mcr-3* in samples from swine and farmers in this study.Table 1ProvincesFarmsNo. of swine samples*mcr-3*-positive rate of pigsNo. of farmer samples*mcr-3*-positive rate of farmersGuangdongGD11660.60% (1)\--GD21220.00% (0)\--GD32083.85% (8)100.00% (0)GD4150.00% (0)\--GD5380.00% (0)\--GD6970.00% (0)200.00% (0)GD71501.33% (2)300.00% (0)GD8500.00% (0)100.00% (0)GD95010.00% (5)102.00% (2)GD10310.00% (0)60.00% (0)GD11494.08% (2)\--GD121466.85% (10)\--AnhuiAH11040.00% (4)20.00% (0)AH25010.00% (5)100.00% (0)AH3490.00% (0)70.00% (0)GuangxiGX1330.00% (0)\--GX2470.00% (0)\--GX3480.00% (0)90.00% (0)GX4412.44% (1)\--HunanHN130.00% (0)\--HN2502.00% (1)\--HN3450.00% (0)\--JiangxiJX110.00% (0)\--JX2791.27% (1)\--HebeiHB500.00% (0)100.00% (0)HeilongjiangHLJ502.00% (1)90.00% (0)HubeiHuB511.96% (1)40.00% (0)JilinJL500.00% (0)10.00% (0)LiaoningLN500.00% (0)70.00% (0)SichuanSC1200.83% (1)2913.79% (4)ShaanxiSX10.00% (0)\--HainanHaiN10.00% (0)\--Total/19512.20% (43)1743.45% (6)

2.3. Bacterial Isolation, Identification and Growth Condition {#s0040}
-------------------------------------------------------------

Fecal samples were collected by sterile rectal swab and sent to the lab immediately. All of the fecal samples were cultured by adding three milliliter enrichment broth and incubated at 37 °C overnight. The negative control was performed in every cultivation and identified eligible. Subsequently, the total DNA was extracted by water-boiling method and screened for the presence of *mcr-3* using PCR as previously described \[[@bb0320]\]. The resulting amplicons were confirmed by sequencing. Screening of MCR-3*-*producing isolates from PCR-positive fecal samples was by inoculating Columbia Blood Agar (Oxoid, Hampshire, United Kingdom) with colistin (2 μg/ml) while species identification was first conducted by the API20E system (bioMérieux, Marcy l\'Etoile, France) and then by MALDI-TOF MS (BrukerDaltonik GmbH, Bremen, Germany). When the species could not be well interpreted by MALDI-TOF, 16S rDNA sequencing was applied.

*E. coli* \[DH5α and BL21 (DE3)\] were used as the gene cloning host and the protein expression host, respectively (Table S3). *E. coli* MG1655, a colistin-susceptible strain, is used to test the ability of *mcr-3* and/or its mutants to confer colistin resistance (Table S3). All bacterial cultures were maintained in the Luria-Bertani (LB) broth. Solid LB agar plates supplemented with appropriate antibiotics were used to either screen the *mcr-3*-containing clones or determine the level of bacterial colistin resistance.

2.4. Measurement of Bacterial Growth {#s0045}
------------------------------------

To address effect exerted on bacterial growth by the *eptA* and/or *mcr-*like genes, the *E. coli* strain MG1655 alone \[or with either the pBAD24 empty vector or plasmid-borne *eptA/mcr* genes\] was subjected to the cultivation at 37 °C (180 rpm) in LB broth (Table S3). Totally, three different versions of *mcr*-like gene used here included *mcr-1*, *mcr-2*, and *mcr-3*, respectively. To generate bacterial growth curves, over-night cultures were inoculated (1:1000) in fresh LB broth (37 °C, 180 rpm) with varied level of arabinose (0.00%, 0.02%, and 0.20%). Spectrophotometer (Spectrum lab S32A) was used to measure the optical density (OD) at 600 nm at a regular interval of one hour for a total of 20 h.

2.5. Plasmid Conjugations and Multi-Locus Sequence Typing (MLST) {#s0050}
----------------------------------------------------------------

Conjugation experiments were performed to test the transferability of the *mcr-3*-harboring plasmid, using a Streptomycin-resistant *E. coli* C600 as the recipient. Briefly, overnight culture of *mcr-3*-positive isolates and recipient strain *E. coli* C600 were mixed (ratio of 1:9) in LB broth, which was subjected to overnight incubation. The mixture was then spread on LB agar plates containing sodium streptomycin (2000 μg/ml) plus colistin (4 μg/ml) to select trans-conjugants that had acquired the *mcr-3*-harboring plasmid. Carriage of such a plasmid in the parental strain and corresponding trans-conjugants was confirmed by PCR and Sanger sequencing. MLST was determined using BLASTn and publicly available database (<http://mlst.warwick.ac.uk/mlst/dbs/Ecoli>) (Table S1).

2.6. Sequencing, Assembly and Annotation of Plasmid Genomes {#s0055}
-----------------------------------------------------------

The acquired *mcr-1/3*-positive plasmids were used to construct a sequencing library using the TruePrepTM DNA Library Prep Kit V2 from Illumina® (Vazyme, USA). The qualified libraries were sequenced on an Illumina HiSeq X-ten platform (Illumina, USA), in which 150 bp paired-end reads were generated. Following removal of low-quality reads with software Trimmomatic \[[@bb0325]\], the high-quality clean reads were assembled into long contigs with the software of SPAdes (version 3.11.0) \[[@bb0330]\]. The assembled contigs with resistance genes were identified and compared to those closely-related plasmids (with known genome sequences deposited in NCBI database) using the program Blastall (version 2.2.22) with an e-value cutoff of 1 × 10^−5^. The suspected gaps between contigs were closed with Sanger quenching of PCR products. RAST \[[@bb0335]\] and GLIMMER (version 3.02) \[[@bb0340]\] were utilized for the prediction of genes on the complete plasmids. The GC content and GC skew analysis of the whole plasmid sequence were performed by homemade Python Scripts. Finally, the plasmid map was drawn with the software of Circos (version 0.69).

2.7. Sequence Data {#s0060}
------------------

GenBank accession numbers of new plasmids with full genome sequences are listed as follow: [MH043623]{.ul} for pGDZJ002--1; [MH043624]{.ul} for pGDZJ003--1; [MH043625]{.ul} for pGDZJ003--2; and [MH043626]{.ul} for pGDZJ004.

2.8. S1-PFGE and Southern Blotting {#s0065}
----------------------------------

The plasmid and/or chromosome location of *mcr-3* and *mcr-1* genes was determined by S1-nuclease digestion and pulsed-field gel electrophoresis (S1-PFGE), followed with southern blotting hybridizations. The *mcr-3*-harboring isolates were suspended in PBS and embedded in gold agarose gel plugs (SeaKem® Gold Agarose, Lonza, USA). The plugs were digested with S1 nuclease (TaKaRa, Dalian, China) and the DNA fragments were separated by PFGE. Southern blotting hybridizations of plasmid DNA were performed with DIG-labelled *mcr-3* or *mcr-1* probes according to the manufacturer\'s instructions (Roche Diagnostics, Germany).

2.9. Antimicrobial Susceptibility Tests {#s0070}
---------------------------------------

We determined minimum inhibitory concentrations (MICs) of colistin, polymyxin B, tigecycline, ampicillin, amoxicillin-clavulanate, cefotaxime, ceftazdime, cefepime, gentamicin, amikacin, ertapenem, imipenem, meropenem, fosfomycin, nitrofurantoin and ciprofloxacin for all isolates using the agar dilution method in accordance with the Clinical and Laboratory Standards Institute guidelines, and we interpreted the results according to the breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2016) for colistin, polymyxin B, and tigecycline and those of the Clinical and Laboratory Standards Institute (CLSI, 2016) for other antimicrobials (Table S2).

2.10. Structure Modeling and Molecular Docking {#s0075}
----------------------------------------------

The software Swiss-Model ([https://swissmodel.expasy.org/interactive/qMEvX5/models/](https://swissmodel.expasy.org/interactive/qMEvX5/models){#ir0015}) \[[@bb0345]\] was used to obtain the modelled structure of MCR-3 using the structure of the *Neisseria meningitidis* EptA (PDB, [5FGN](pdb:5FGN){#ir0020}) as the template \[[@bb0350]\]. Although MCR-3 shows only 37.55% identity to EptA, its modelled structure exhibits the coverage score of 98% (6--540). It was evidently a qualified structural prediction, in which GMQE (Global Model Quality Estimation) is 0.73, and QMEAN (quality estimation on the modelled structure) is −3.68. The ready-to-dock 3D structure of phosphatidylethanolamine (PE) (ID: ZINC32837871) and head group of PE (ID: ZINC02798545) was obtained from ZINC database \[[@bb0355]\]. As we recently described with EptA/MCR-1 \[[@bb0360]\], the program DOCK6.7 was used to dock the PE ligand to designated binding pocket into MCR-3 \[[@bb0365]\].

2.11. Overlap Extension PCR and Site-directed Mutagenesis {#s0080}
---------------------------------------------------------

Using appropriate primers (Table S3), overlap extension PCR was conducted, generating the hybrid derivatives of MCR-1/3 and Z1140 \[[@bb0150]\]. Site-directed mutagenesis was applied to produce all the point-mutants of *mcr-3* \[[@bb0135], [@bb0150], [@bb0360]\]. The Mut Express II Fast Mutagenesis Kit V2 (Vazyme Biotech Co.,Ltd) was used along with specific primers for *mcr-3* (Table S3).

2.12. Expression and Identification of MCR-3 Membrane Protein {#s0085}
-------------------------------------------------------------

To produce MCR-3 integral membrane protein, the strain FYJ1153 (BL21 with pET21a*::mcr-3*) was engineered (Table S3). As we descrbed with MCR-1/2 \[[@bb0150], [@bb0360]\], the expression of MCR-3 was induced by the addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The bacterial pellets were harvested and lysed through a French Press (JN-Mini, China) \[at 500 p.s.i. once and 1300 p.s.i twice\]. Following the routine purification process for the membrane proteins MCR-1/2, MCR-3-containing fraction solubilized in buffer B \[20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 5% glycerol, 1% detergent dodecyl-β-D-maltoside (DDM, M/V)\] were incubated overnight with pre-equilibrated Ni-NTA agarose beads at 4 °C. Then, the intramembrane protein MCR-3 was eluted from the Ni-NTA agarose beads using the elution buffer \[20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 100 mM immidazole, 5% glycerol (vol/vol), 0.03% DDM (M/V)\]. The acquired protein was concentrated with a 30 kDa cut-off ultra-filter (Millipore, USA), and analyzed with 12% SDS-PAGE. To further verify its identity of recombinant MCR-3, the expected protein bands were cut from the SDS-PAGE, digested with Trypsin (G-Biosciences St. Louis, MO), and subjected to the confirmation with A Waters Q-Tof API-US Quad-ToF mass spectrometer \[[@bb0370], [@bb0375]\]. Finally, data analyses were conducted using the Waters Protein Lynx Global Server 2.2.5, Mascot (Matrix Sciences) and BLAST against the NCBI nr database.

2.13. Circular Dichroism Analyses {#s0090}
---------------------------------

The protein secondary structure of MCR-3 was determined using circular dichroism (CD) \[[@bb0360]\]. Prior to CD analyses, MCR-3 protein (\~0.2 mg/ml) was dissolved in Tris-buffer \[20 mM Tris-HCl, 300 mM NaCl, 0.03% DDM, 10% (vol/vol) glycerol, pH 8.0)\]. For every experiment, \~600 μl protein sample was dropped into a quartz cylindrical cuvette. The CD spectra were recorded on a Jasco Model J-1500 spectrometer (Jasco Corp., Tokyo, Japan) through continuous wavelength scanning (in triplicate) from 200 to 260 nm at a scan rate of 50 nm/min \[[@bb0380]\] and smoothed with a Savitsky-Golay filter \[[@bb0385]\].

2.14. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) {#s0095}
-----------------------------------------------------------

As recently demonstrated with MCR-1 \[[@bb0360]\], ICP-MS was adopted to examine the protein-bound zinc in MCR-3. The MCR-3 protein sample was subjected to an NexION™ 300× ICP-MS instrument (PerkinElmer, USA) in which the mass-to-charge ratio (*m/z*) was calculated \[[@bb0390]\]. The carrier gas was helium.

2.15. Assays for Enzymatic Reaction of MCR-3 {#s0100}
--------------------------------------------

As recently showed for EptA \[[@bb0395]\] and MCR-1/2 \[[@bb0360], [@bb0395]\] and ICR-Mo \[[@bb0220]\], the reaction catalyzed by MCR-3 in vitro was conducted. In brief, the 1-acyl-2-{12-\[(7-[n]{.ul}itro-2-1,3-[b]{.ul}enzoxadiazol-4-yl) amino\] [d]{.ul}odecanoyl}-sn-glycero-3-[p]{.ul}hospho[e]{.ul}thanol[a]{.ul}mine (Avanti Lipids, USA), acted as the substrate for MCR-3, which is abbreviated as NBD-PEA. The reaction system (50 μl in total) consisted of the following components \[50 mM HEPES (pH 7.50), 100 mM NaCl, 0.03% of DDM, 0.2 mM NBD-PEA and 40 μM MCR-3\] and kept for 20 h at room temperature. Subsequently, the reaction products were separated with thin layer chromatography (TLC) in a mobile phase consisting of ethyl acetate: methanol: water (7:2:1, vol/vol). The fluorescent signal on the TLC plate was visualized under Epi blue light (455--485 nm) with a gel imaging system (Bio-Rad) as Anandan et al. described \[[@bb0350]\].

2.16. Preparation and Structural Determination of Lipopolysaccharide-Lipid A {#s0105}
----------------------------------------------------------------------------

The crude lipopolysaccharide (LPS) was extracted as described by Caroff et al. \[[@bb0130], [@bb0400]\] with modifications. The resulting LPS species were freeze-dried, and then dissolved in the buffer of 30 mM Tris-HCl \[pH 8.0\] containing 0.2% SDS. DNase I (25 μg/ml) and RNase A (100 μg/ml) were used to remove the nucleic acid contamination. The removal of protein contaminants was proceded via 1 h of treatment with proteinase at 37 °C. To release the Kdo linkage from lipid A, the crude LPS was heated at 100 °C for 1 h in the sodium acetate buffer (10 mM, pH 4.5) supplemented with aqueous 0.2% SDS. Then, the residual SDS was cleaned through the precipitation with acidified ethanol \[[@bb0405]\].

SDS-PAGE coupled with silver staining was utilized to detect the purity of lipid A pools from different bacterial strains \[[@bb0410]\]. The qualified lipid A species were subjected to MALDI-TOF/TOF-MS (Bruker, ultrafleXtreme) in negative-ion mode with the linear detector \[[@bb0115], [@bb0415]\]. Briefly, the samples of lipid A were dissolved in 20 ul of chloroform: methanol (2:1) solution and then loaded onto the MALDI sample plate, giving MS spectrum. In general, each spectrum was collected from an average of 500 shots and 50% laser power \[[@bb0130], [@bb0400], [@bb0420]\].

2.17. Liquid Chromatography Mass Spectrometry (LC/MS) {#s0110}
-----------------------------------------------------

The LC/MS system (Agilent technologies 6460 Triple Quad LC/MS) was applied in structural measurement of the alternative lipid substrate, NBD-Glycerol-3-PEA \[[@bb0425]\]. Similarly, the reaction mixture catalyzed by MCR-3 was assayed. In the trials of GC/MS, the analytical chromatographic column \[Zorbax SB C18 (2.1\*50 mm, 3.5 μm)\] was utilized. The samples were eluted with methanol/0.1% methanoic acid (95:5) at 0.3 ml/min. Of particular note, an electrospray ionization (ESI) source was connected with mass spectrometry (MS), and the positive ion scanning appeared in the mode of neutral loss ion (*m/z*, 141).

2.18. Confocal Microscopy {#s0115}
-------------------------

Confocal microscopy was applied in both the determination of ROS level and the differentiation of ALIVE/DEAD status of *E. coli*. First, to evaluate the potential effects of MCR-3 (and/or EptA) on colistin-induced ROS production, the *E. coli* strains with or without the gene of *mcr-3*/*eptA* were subjected to confocal microscopy analyses. All the *E. coli* strains in mid-log phase \[OD600 = \~0.8\] (Table S3) were divided into two equal fractions: one half acted as control, the remaining fraction was challenged with 4 μg/ml colistin for 0.5 h. The oxidant-sensitive dye used for ROS detection was 2′,7′-[d]{.ul}i[c]{.ul}hlorodihydro[f]{.ul}luorescein [d]{.ul}i[a]{.ul}cetate (DCFH~2~DA, Sigma). The fluorescent images were captured with a Zeiss LSM 510 Meta confocal laser scanning microscope (100× oil immersion objective), in which the fluorescence of [d]{.ul}i[c]{.ul}hloro-[f]{.ul}luorescein (DCF, an oxidation product of DCFH~2~DA) was excited by 488 nm, and resultant emission was detected at 530 nm \[[@bb0430]\].

To further determine bacterial viability, confocal microscopy-based LIVE/DEAD assays were conducted as Yang et al. described with little change \[[@bb0435]\]. The strains tested here are same as those of growth curves. In brief: it can be described as follows: i) overnight cultures were sub-cultured into 5 ml LB broth and incubated for 16 h 37 °C (180 rpm); ii) bacterial culture was concentrated via 10 min of centrifugation at 4000 rpm, gently removing the supernatant, and the dissolved pellets were further incubated for 8 h in fresh LB broth with/without arabinose (0.2%, *w*/*v*); iii) after the second round of spinning at 4000 rpm for 10 min, the resultant pellet was washed twice with 0.085% NaCl; iv) bacterial bio-film was stained with the kit of LIVE/DEAD® (*v*/v; BacLight TM Bacterial Viability Kit, Invitrogen) in the solution of 0.085% NaCl (of note: 3 μl of the dye mixture was added to each 1 ml of the bacterial suspension, mixed thoroughly at room temperature in the dark, and kept for 15 min); v) the images were obtained by the Confocal Laser Scanning Microscopy (CLSM, Zeiss LSM 800) with a 63× oil immersion lens. The CLSM images were analyzed using COMSTAT image analysis software for quantification of biofilm biomass. The COMSTAT data was evaluated using one-way ANOVA followed by Tukey-Kramer Multiple comparison post hoc test. Statistical significance was set at *p* \< .05.

2.19. Chemical Rescue Tests {#s0120}
---------------------------

Accumulating evidence suggests that the hydroxyl radical death pathway could be activated as a downstream event of colistin exposure \[[@bb0440], [@bb0445]\]. The fact that MCR-3 can modify lipid A moieties of LPS on bacterial membrane, an initial target of colistin, allowed us to hypothesize that expression of MCR-3 might physiologically prevent colistin-induced ROS production. To test this hypothesis, chemical rescue experiments were conducted routinely using two ROS inhibitors: bipyridine (the ferric chelator) and L-cysteine (a ROS scavenger). To compare the bacterial survival, *E. coli* strains (with or without *mcr-1*) were subjected to the different challenges as follows: i) the treatment of colistin alone; ii) the combined treatment of colistin plus 2,2′-dipyridine \[[@bb0450]\]; iii) the stress of colistin mixed with L-cysteine \[[@bb0455]\]. Briefly, overnight cultures were sub-cultured at a ratio of 1: 500 into LB medium for \~5 h to OD600 nm of 1. For the iron chelation, 2,2′-dipyridine (500 μM, Sangon Biotech) was added simultaneously with colistin (20 μg/ml, Sigma). As for the ROS quenching experiments, L-cysteine (10 mM, Sangon Biotech) was mixed simultaneously with colistin (20 μg/ml, Sigma). Following a 0.5 h growth at 37 °C, cultures were centrifuged at 1800 *g* for 5 min. The pellets were re-suspended with 1× PBS (pH 7.2) and serially diluted. 5 μl of 3 selected dilutions \[[@bb0050]--[@bb0025]\~[@bb0050]--[@bb0035]\] were dropped onto LB agar plates. After overnight incubation at 37 °C, colony forming units (CFU) were enumerated \[[@bb0460]\].

2.20. Phylogenetic Tree {#s0125}
-----------------------

The amino acid sequence of MCR-3 was used as a query to identify similar protein sequences using protein BLAST with options enabled to exclude models and uncultured environmental samples. The default parameters were modified to reduce the word size to 2 and to return 500 target sequences. Sequences of distantly related MCR proteins including those in the MCR-1/2/4/5 family were manually included to obtain a comprehensive analysis. Redundant sequences were eliminated using the Unique seq server (<https://www.ncbi.nlm.nih.gov/CBBresearch/Spouge/html_ncbi/html/fasta/uniqueseq.cgi>) and aligned using MUSCLE ([https://www.ebi.ac.uk/Tools/msa/muscle/](https://www.ebi.ac.uk/Tools/msa/muscle){#ir0030}). In total, 511 unique amino acid sequences were utilized for the subsequent phylogenetic analysis.

jModeltest (via MEGA 7) was used to identify the best-fit protein substitution model and the best model was used to generate a maximum-likelihood tree with 1000 bootstrap replicates. A LG model with Gamma distribution and Invariant sites was used. Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior log likelihood value. The results are presented as a radial phylogram. A subset of the sequences was re-analyzed using the about method to obtain a smaller, more detailed phylogenetic tree.

2.21. Role of the Funding Source {#s0130}
--------------------------------

The funder had no role in the study design, data collection, data analysis, data interpretation, or writing of the article. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

3. Results {#s0135}
==========

3.1. Molecular Epidemiology of *mcr-3* in China {#s0140}
-----------------------------------------------

Of the 6497 unique samples collected, a total of 6497 non-duplicate samples were collected from thirteen provinces in China, from Oct 2016 to Dec 2017. Of them, 49 samples (49/6497 = 0.75%) were *mcr-3* positive when verified by PCR and Sanger sequencing. Specifically, 3.45% (6/174) of samples from farmers were *mcr-3* positive, followed by 2.20% (43/1951) from swine-derived samples. None of the *mcr-3*-positive samples were from patients or other healthy individuals. In addition, 14.02% (911/6497) samples were *mcr-1*-positive. In particular, *mcr-3*-positive samples were identified in 8 out of 13 provinces, namely Guangdong, Guangxi, Heilongjiang, Anhui, Hubei, Jiangxi, Hunan and Sichuan ([Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}). The rate of incidence of *mcr-3* was as low as 0.59% in the isolates from Guangxi to as high as 8.26% from Anhui ([Fig. 1](#f0005){ref-type="fig"}). No *mcr-3* was detected in the neighboring provinces of Hebei, Jilin, Liaoning, Shaanxi and Hainan ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Dissemination of *mcr-3* (and/or its variants) in swines of China.Shandong Province where *mcr-3* is initially detected \[[@bb0320]\] is highlighted with green boundary. Those with *mcr-3*-positive isolates in our study are labelled with red boundaries, whereas those without *mcr-3*-positive isolates are indicated with black boundaries. Of note, a *mcr-3* variant, *mcr-3.7*, was recently detected in Sichuan Province of China \[[@bb0270]\].Fig. 1

We randomly chose 8 isolates out of 49 *mcr-3*-positive samples for microbial analyses (Table S1). All the 8 *mcr-3*-carrying isolates were resistant to colistin and polymyxin B. Most of them were susceptible to cefotaxime (6 of 8 isolates), ceftazdime (7 of 8 isolates), cefepime (8 of 8 isolates), gentamicin (5 of 8 isolates), amikacin (8 of 8 isolates), ertapenem (7 of 8 isolates), imipenem (8 of 8 isolates), meropenem (8 of 8 isolates), fosfomycin (7 of 8 isolates), tigecycline (8 of 8 isolates), only some of the isolates remained susceptible to amoxicillin-clavulanate (1 of 8 isolates), nitrofurantoin (4 of 8 isolates), ciprofloxacin (4 of 8 isolates) and one isolate was susceptible to ampicillin (1 of 8 isolates) (Table S2). We further investigated the plasmids harboring *mcr-3*. In conjugation experiments, *mcr-3*-bearing plasmids were successfully transferred to *E. coli* C600 in 4 out of 8 *mcr-3*-carrying isolates, and 2 of 8 exhibited high conjugation rates (\~10^−3^) (Table S1). Five isolates co-carried *mcr-1*, 2 of which were on plasmids and successfully transferred to *E. coli* C600. S1-PFGE and southern blotting of 8 *mcr-3*-positive isolates and their trans-conjugants showed that *mcr-3* genes were located on plasmids with sizes of \~35-kb, \~48-kb, \~210-kb and \~240-kb, whereas *mcr-3* genes of GDZJ005, GDZJ006, GDZJ007 and GDZJ008 were not successfully transferred to *E. coli* C600. The *mcr-3* genes of GDZJ005, GDZJ006, GDZJ007 and GDZJ008 were located on plasmids, which is based on S1-PFGE and Southern blot. (Fig. S1). In addition, we identified two novel variants of *mcr-3* from 3 isolates, namely *mcr-3.4* and *mcr-3.7* (Table S2 and Fig. S4). This brings the number of *mcr-3* variants up to eleven (Table S2).

3.2. Comparative Genomics of *mcr-3*-Harboring Plasmids {#s0145}
-------------------------------------------------------

We succeeded in sequencing of MCR-3-producing plasmids pGDZJ002-1, pGDZJ003--2 and pGDZJ004 from GDZJ002, GDZJ003 and GDZJ004, respectively, and *mcr-1*-encoding plasmid pGDZJ003-1 from the GDZJ003. Of the two plasmids isolated from GDZJ003, whole genome sequencing shows that plasmid pGDZJ003--2 is a 50,537 kb plasmid that contains 73 ORFs including the *mcr-3.7* gene. MCR-3.7 has 18 amino acid substitutions when compared to MCR-3. This IncP-type plasmid is also seen to possess the *tra* and *trb* conjugative regions, portioning modules *par*, replication initiator *trfA*, host-lethal protein encoding genes *klc* and their regulators *kor* and a toxin-antitoxin system *higA-B* ([Fig. 2](#f0010){ref-type="fig"}B)*.* It shows very high sequence identity to another IncP-type *mcr-3.7-*bearing plasmid pMCR3_WCHEC-LL123 \[[@bb0270]\] (Accession no.: MF489760) isolated from human isolates of *E. coli*. However, unlike pMCR3_WCHEC-LL123, pGDZJ003--2 is missing the insertion sequence IS*1294* ([Fig. 2](#f0010){ref-type="fig"}C) and does not have additional antibiotic resistance genes like *bla*~TEM~ (conferring ampicillin resistance). When compared to another IncP type *mcr-1*-carrying plasmid, pMCR_1511 \[[@bb0465]\], pGDZJ003--2 also lacks the transposition unit of *mcr-1* (IS*Apl1*-*mcr-1*-hp) on pMCR_1511 ([Fig. 2](#f0010){ref-type="fig"}D). The other plasmid from GDZJ003 is pGDZJ003-1 which harbors the *mcr-1* gene and is 33,522 kb in length with a GC content of 42%. This plasmid contains 43 predicted ORFs, with 17 associated with formation of the type IV pilus ([Fig. 2](#f0010){ref-type="fig"}A). Comparative analysis shows that its backbone is very closely related to two narrow-host-range IncX4-type plasmids \[[@bb0470]\] pSH146-32 (Accession no.: JX258655) and the *mcr*-*1*-harboring plasmid pCSZ4 \[[@bb0475]\] (Accession no.: KX711706) ([Fig. 2](#f0010){ref-type="fig"}C). Like most IncX4 plasmids, both pCSZ4 and pGDZJ003--1 are missing the IS*Apl1* insertion sequence in front of the *mcr*-*1* gene.Fig. 2Comparative genomics of the plasmids carrying *mcr-3* and/or *mcr-1* genes.A. Genomic map of the *mcr-1*-bearing plasmid pGDZJ003\_*mcr-1* that coexists with the *mcr-3.7*-harboring plasmid pGDZJ003\_*mcr-3.7* in *E. coli.*B. Schematic representation for circular genome of the *mcr-3.7*-harboring plasmid pGDZJ003\_*mcr-3.7.*Circles (from inside to outside) separately denote the GC screw, GC content and the open-reading frames in both DNA strands \[[@bb0135]\]. The plasmid sequences were annotated by RAST, and the maps were generated using Circos program \[[@bb0135]\].C. Colinear genomic analyses of three plasmids pGDZJ003\_*mcr-1*, pSH146--32 and pCSZ4.D. Linear genome alignment of the *mcr-3*-positive plasmid pGDZJ003\_*mcr-3.7* with the other two plasmids (pMCR3_WCHEC-LL123 and pMCR_1511).Fig. 2

Similarly, genome sequences for two other *mcr-3*-carrying plasmids, pGDZJ002-1 (50,818 kb; Fig. S2) and pGDZJ004 (50,519 kb; Fig. S3) were obtained. Both plasmids have a GC content of 47% and contain similar elements for replication, conjugation, and partitioning (Figs S2 and S3). Colinear genome analysis of pGDZJ003--2 and pMCR3_WCHEC-LL123 shows that they possess similar genetic arrangements (Fig. S4) and belong to the IncP family of plasmids. Except for little bite of SNPs and deletions of short fragments, both pGDZJ002--1 and pGDZJ004 carry the *mcr-3* gene within the same context as pGDZJ003--2 and pMCR3_WCHEC-LL123, which carry the *mcr-3* variant, *mcr-3.7* instead. However, unlike pMCR3_WCHEC-LL123, the other 3 plasmids do not contain IS*1294* (Fig. S4). Together, these plasmids are additive members of the *mcr-1*-carrying (pGDZJ003-1) and *mcr-3*-carrying family of plasmids (pGDZJ002-1, pGDZJ003--2 and pGDZJ004). *mcr*-like genes have been increasingly identified on plasmids of multiple incompatibility groups within a wide range of bacterial hosts. Though these plasmids were isolated from diverse hosts, their frequent sharing of similar genetic elements suggests a common evolutionary origin.

3.3. Evolution of MCR-3 {#s0150}
-----------------------

We utilized phylogenetic analysis to try and understand the evolution of MCR-3, which shares a closer homology to *Neisseria* EptA (53.1%) than MCR-1 (44.1%) using MCR-3 as a template, \>500 homologs with \>95% sequence coverage and 60% identity were identified via blastp and compared with representative protein sequences from the MCR-1/2/P families. The radial phylogram shows three broad groups within the MCR-3 family and their homologs and a fourth distinct and detached group consisting of the MCR 1/2/P family ([Fig. 3](#f0015){ref-type="fig"}A). The first group primarily consists of MCR-3-like genes exclusively from the *Aeromonas* species. One branch from this group consists of MCR-3 and its variants (MCR-3.1, MCR-3.2, MCR-3.4, MCR-3.7, MCR-3.9, MCR-3.10) ([Fig. 3](#f0015){ref-type="fig"}B). This branch is surrounded by other MCR-3-like genes that encode putative PE-transferases from *Aeromonas* species ([Fig. 3](#f0015){ref-type="fig"}A), primarily found in fresh and brackish water but also implicated in human infections. The second group consists of paraphyletic branches with PE-lipid A transferases from several bacterial genera including *Thalassospira, Rahnella, Hafnia, Edwardsiella, Buttiauxella* and *Enterobacter,* some of which are normal human commensals that have been reported to be resistant to a number of antibiotics (e.g., *Hafnia* spp.), while others (e.g., *Edwardsiella* spp.) are naturally resistant to colistin. The third group consists of other putative PE-lipid A transferases from *E. coli* and *Vibrio*/*Photobacterium* species. The marine bacterium *Photobacterium damselae* is a human and fish pathogen with colistin resistance \[[@bb0480]\]. The *E. coli* members of this group form a very tight subclade. One of these members, *E. coli* O157:H7 strain EDL933 containing a putative PEA-transferase Z1140 was tested experimentally and conferred no appreciable colistin resistance on LB agar plates (\<0.5 μg/ml) (Fig. S9). Swapping the transmembrane domain of MCR-3 with that from Z1140 still maintained activity (8 μg/ml) (Fig. S9). The fourth subclade is further organized into 2 sub-groups: i) MCR-1/2 and their point mutant variants; ii) MCR-P(M）and other transitional intermediates of the MCR-1/2 family from *Moraxella* spp. ([Fig. 3](#f0015){ref-type="fig"}B). MCR-1/MCR-2 represent a group undergoing rapid evolution with the MCR-P(M) family serving as a potential reservoir of chromosomally-encoded transitional intermediates in the evolution of the MCR-1/2 family ([Fig. 3](#f0015){ref-type="fig"}B). Surprisingly, *Neisseria* EptA, a chromosomal colistin resistance determinant ([Fig. 3](#f0015){ref-type="fig"}A) is an evolutionarily-distant member.Fig. 3Phylogeny of MCR-3.A. A radial representation of a phylogenetic tree of MCR-3 and its homologs.Protein sequences of MCR-1 homologs are included in the analysis as a reference for evolutionary distance from transferable colistin resistance. Four distinct subclades are observed and are clustered as two distinct groups: MCR-3 like proteins (in light blue) with MCR-3 variants highlighted (in blue), Intrinsic determinants (in orange), *Vibrio* species (in pink) and MCR-1/2 proteins and their progenitors (in green). MCR-3 is highlighted in Bold font.B. An unrooted phylogenetic tree of MCR-3 and its close homologs.Two distinct subclades are observed: i) Subclade I with MCR-3 variants and MCR-3-like genes ii) MCR-1/2 variants and their progenitors. Paraphyletic branches within each subclade are indicated in different colors, MCR-3 variants (in light blue), MCR-3 like proteins (in blue), MCR-1/2 (in light green) and MCR-1/2 progenitors (in dark green), MCR-3 and MCR-1 is highlighted in bold font. Asterisk denotes \>4 amino acid substitutions in comparison to MCR-3.The evolutionary history of MCR-3 was inferred using the maximum likelihood method. The trees presented here have been inferred from 1000 bootstrap replicates using a LG amino acid substitution model. The percentages of replicate trees in which the associated taxa are clustered in the bootstrap test (1000 replicates) are shown next to the branches. A discrete gamma distribution was used to model evolutionary rate differences among sites with some evolutionarily invariable sites.Protein accession numbers of individual members have been indicated in the figure.Given that it is a putative member of PEA lipid transferase without detectable activity conferring colistin resistance, Z1140 of the *E. coli* O157:H7 EDL933 is used here as an internal reference for phylogeny.Fig. 3

The findings indicate that MCR-3 and its variants share a common ancestor with MCR-like proteins from *Aeromonas* species and constitute a rapidly evolving branch of transferable colistin resistance genes that are more closely related to chromosomally encoded intrinsic determinants found in commensal and environmental bacteria. *Aeromonas* species might occupy an unexplored niche in the marine ecosystem that is yet to be examined for colistin resistance. A complete biochemical and physiological study of MCR-3 is missing and would provide a better understanding of its evolutionary pattern.

3.4. Characterization of MCR-3 Intramembrane Protein {#s0155}
----------------------------------------------------

Predictions with the TMHMM server v2.0 (<http://www.cbs.dtu.dk/services/TMHMM>) suggest that MCR-3 is an integral membrane protein possessing five N-terminal helices (Fig. S5A), which is almost identical to those of MCR-1 \[[@bb0135]\], MCR-2 \[[@bb0150]\] and EptA \[[@bb0095]\]. The hexa-histidine-tagged MCR-3 protein was tracked throughout the purification process (via Ni affinity chromatography) by Western blot with an anti-6× His antibody (Fig. S6A). The purified MCR-3 protein was visualized by 12% SDS-PAGE and its mass was estimated to be around 60 kDa (Fig. S6B). Its exact mass was then determined to be 61.3 kDa (Fig. S7C) by MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) and its sequence identity was verified by peptide mass fingerprinting followed by MALDI-TOF MS with a 56.4% fragment coverage (Fig. S8D). Further, the secondary structure and folding properties of MCR-3 were determined using circular dichroism (CD). The spectrum obtained had negative dips at 208 nm and 222 nm, characteristic of alpha helices (Fig. S6E) and consistent with earlier observations made for MCR-1 \[[@bb0135]\] and MCR-2 \[[@bb0150]\]. More importantly, consistent with crystallographic evidence \[[@bb0135], [@bb0155], [@bb0160], [@bb0165], [@bb0170]\], our results indicate the presence of protein bound zinc in full-length MCR-3 (Fig. S6F). This was measured using inductively coupled plasma mass spectrometry (ICP-MS). In agreement with our recent biophysical description of MCR-1 and its derivatives \[[@bb0360]\], MCR-3 seemed to be well expressed and purified to homogeneity while maintaining its structural integrity.

MCR-3 was modelled (Fig. S6G) against the structure of full-length EptA (PDB: [5FGN](pdb:5FGN){#ir0040}) \[[@bb0350]\] using Swiss-Model ([https://swissmodel.expasy.org/interactive/qMEvX5/models/](https://swissmodel.expasy.org/interactive/qMEvX5/models){#ir0045}) \[[@bb0345]\] with a coverage of 98%. The model was found to retain a similar topology \[[@bb0350]\], despite possessing only 37.55% identity to EptA (Fig. S5B). As observed with EptA \[[@bb0350]\], the overall architecture of MCR-3 contains an N-terminal trans-membrane (TM) domain and a periplasm-facing catalytic domain at C-terminus (Fig. S6G). The catalytic domain has a hydrolase-fold (Fig. S6G) comprising 10 α-helices and 7 β-sheets (Figs S5B and S6G). This is connected to a TM domain containing six α-helices (Fig. S5A) by four short periplasmic loops (PH2, PH2', PH3 and PH4), a bridge helix (BH) and a long-coiled loop (Figs S5B and S6G). Certain residues (Fig. S5B) within these structural elements are found to be deeply conserved via amino acid sequence alignments between MCR-1, MCR-2, EptA and MCR-3. These include five potential zinc-interacting residues (E238, T277, H375, D450 and H451, [Fig 6](#f0030){ref-type="fig"}A--B) and seven possible PE substrate-binding residues (N103, T107, E111, G322, K325, H380, and H463, [Fig 6](#f0030){ref-type="fig"}C-D), consistent with experimental evidence from EptA \[[@bb0350]\] and MCR-1 \[[@bb0360]\]. The roles of these residues in MCR-3 catalytic activity require further biochemical analysis.

3.5. Enzymology of MCR-3 Catalysis {#s0160}
----------------------------------

In an in vitro reaction with a fluorescent substrate NBD-glycerol-3-PEA, ([Fig 5](#f0025){ref-type="fig"}A-B), MCR-3 catalyzes the production of NBD-glycerol ([Fig. 5](#f0025){ref-type="fig"}C) from the substrate. NBD-glycerol-3-PEA ([Fig. 5](#f0025){ref-type="fig"}B) is observed as a faster migrating product when separated on a TLC. Presence of both the substrate and the product were further confirmed by liquid chromatography mass spectrometry (LC/MS). This clearly demonstrated that MCR-3 can enzymatically catalyze the removal of the PEA moiety from the lipid substrate in vitro like other well studied PEA transferases such as MCR-1 and MCR-2. Through MALDI-TOF MS, this PEA group is shown to modify the Lipid A of a clinically isolated, *mcr-3*-carrying *E. coli* strain GDZJ002 and its *E. coli* conjugant C600-GDZJ002. The observance of a PPEA-1(4′)-lipid A peak \[*m/z* 1919.806 ([Fig. 5](#f0025){ref-type="fig"}E) or 1919.632 ([Fig. 5](#f0025){ref-type="fig"}F)\] in addition to the unmodified lipid A peak \[m/z 1796.665 ([Fig. 5](#f0025){ref-type="fig"}E) and 1796.541 ([Fig. 5](#f0025){ref-type="fig"}F)\] demonstrates that the PEA moiety is enzymatically cleaved from the PE lipid substrate and is transferred to lipid A.

To unequivocally demonstrate that MCR-3 is responsible for the modification of lipid A in vivo*,* we engineered an *E. coli* MG1655 strain carring an arabinose-inducible plasmid pBAD24-borne *mcr-3*. Through MALDI-TOF MS, lipid A isolates from MG1655 or MG1655 with an empty pBAD24 vector showed the presence of a single peak \[m/z 1796.46 ([Fig. 7](#f0035){ref-type="fig"}A) or 1796.377 ([Fig. 7](#f0035){ref-type="fig"}B)\] corresponding to bis-phosphorylated hexa-acylated lipid A, similar to the unmodified peak observed in the clinical strains above ([Fig 5](#f0025){ref-type="fig"}E--F). Minor strain to strain variations were observed in the mass of unmodified lipid A. The expression of *mcr-3* lead to the production of an additional peak at m/z 1920.803 ([Fig. 7](#f0035){ref-type="fig"}C) corresponding to a single addition of a PEA group (mass difference of 123) to lipid A ([Fig. 5](#f0025){ref-type="fig"}D). The position of this addition may be at the 1 or 4′ position.

Given the similarity between the Thr280-PEA adduct seen in EptA \[[@bb0350], [@bb0490]\] and its counterparts in reactions involving alkaline phosphatase-type phosphate transferases \[[@bb0495]\] along with the in vivo and in vitro evidence presented before, it can be hypothesized that in the first half of the reaction, MCR-3 binds to the PE lipid substrate and releases diacyl glycerol, resulting in a MCR-3 bound PEA adduct ([Fig. 5](#f0025){ref-type="fig"}A). In the second half-reaction, PEA is transferred from this adduct to the 1(4′)-phosphate position of lipid A GlcN moieties, generating PPEA-4′- lipid A ([Fig. 5](#f0025){ref-type="fig"}D). Thus, MCR-3 might utilize a "ping-pong" mechanism of catalysis like that observed in EptA \[[@bb0350]\].

3.6. Mechanistic Insights into MCR-3 Polymyxin Resistance {#s0165}
---------------------------------------------------------

To understand the relationship between the two domains of MCR-3 observed in the modelled structure and the evolution of its function from MCR-like enzymes such as EptA and MCR-1, we utilized domain swapping analysis to engineer four hybrid proteins as denoted below: i) TM1-MCR-3, MCR-3 catalytic domain and TM region of MCR-1; ii) TM3-MCR-1, MCR-1 catalytic domain with TM from MCR-3; iii) TM-MCR-3, MCR-3 catalytic domain with TM of EptA; iv) TM3-EptA, catalytic domain of EptA fused to TM3 of MCR-3 ([Fig. 4](#f0020){ref-type="fig"}A). The chimeric proteins expressed as well as the full-length proteins, as evaluated by western blot ([Fig. 4](#f0020){ref-type="fig"}B). Further, functional assays for resistance to colistin indicated that in *E. coli* MG1655, all four hybrids were susceptible to colistin in MIC assays \[0.25 μg/ml\] ([Fig. 4](#f0020){ref-type="fig"}C), indistinguishable from the negative controls (strain with either no plasmid or empty vector). In contrast, expression of the full-length proteins, MCR-1, EptA and MCR-3, allowed the *E. coli* strain to tolerate 4 μg/ml, 2 μg/ml and 2 μg/ml of colistin, respectively ([Fig. 4](#f0020){ref-type="fig"}C). The incompatibility of the TM and PEA transferase domains of MCR-3 and EptA or MCR-1/2 ([Fig. 4](#f0020){ref-type="fig"}A) hints at an evolutionary distance between them ([Fig. 3](#f0015){ref-type="fig"}).Fig. 4Domain-swapping analyses of MCR-3 and its two paralogues (MCR-1 plus EptA).A. Scheme for domain-swapped constructs between MCR-3 and MCR-1 (or EptA).B. Western blot analyses for the expression of *mcr-3* and its mosaic versions in *E. coli.*C. Measurement of colistin MIC of *E. coli* strains carrying *mcr-3* and its hybrid derivatives.Fig. 4

To obtain detailed experimental evidence regarding the specific residues responsible for PE substrate binding, we utilized molecular docking (MD) to analyze the modelled structure of MCR-3 with its physiological substrate, PE ([Fig. 6](#f0030){ref-type="fig"}A and C). By comparing similarly docked models of MCR-1, MCR-2 and the X-ray structure of EptA \[[@bb0350]\], we propose a similar cavity (Figs S7A--D) that accommodates the substrate in all three enzymes. This is also observed through multiple sequence alignments of the amino acid sequences of these four proteins (Fig. S5B). Using, MSA and MD data, the substrate binding cavity in MCR-3 has been defined by 12 residues of which five (E238, T277, H375, D450 and H451) seem to be involved in the interaction with zinc ([Fig. 6](#f0030){ref-type="fig"}D and S8A) and seven (N103, T107, E111, G322, K325, H380 and H463) are implicated in the recognition of the substrate, PE ([Fig. 6](#f0030){ref-type="fig"}B and S8B). 11 of these 12 residues are highly conserved between MCR-3, MCR-1, MCR-2 and EptA (Figs S8 and S5B) except for a glycine (G322) in MCR-3 instead of a conserved serine in EptA, MCR-1 and MCR-2 (S325, S330 and S328, respectively).

The catalytic role of these sites was experimentally confirmed by generating 12 alanine point mutants of MCR-3 and demonstrating their enzymatic effectiveness using colistin resistance assays and MS analysis of the target lipid A. Empty vector (0.25 μg/ml) and plasmid-free *E. coli* (0.25 μg/ml) were susceptible to colistin and showed a single dominant MS peak corresponding to hexa-acylated lipid A species (*m/z*, 1797.75) while full-length MCR-3 (2 μg/ml) was resistant to colistin and its expression results in the appearance of an additional spectral peak at *m/z* 1920.803 corresponding to the addition of a PEA moiety (123 mass units) to the wildtype lipid A. All twelve alanine mutants express well in *E. coli,* as verified by western blot ([Fig. 6](#f0030){ref-type="fig"}E). Mutants with alanine substitutions in the zinc-binding residues cannot support growth in the presence of colistin ([Fig. 6](#f0030){ref-type="fig"}E) and cannot modify lipid A (unmodified peak at *m/z* 1796.305-1796.632) ([Fig. 6](#f0030){ref-type="fig"}A--O) indicating their importance in enzymatic activity. Of the PE-binding residues, four are completely non-functional with respect to colistin resistance (0.25 μg/ml) and modification of lipid A ([Fig. 6](#f0030){ref-type="fig"}A-O). Two others retain partial activity \[N103A (1 μg/ml) and T107A (0.5 μg/ml)\] while one mutant \[G322A (2 μg/ml)\] shows no phenotypic defect as judged by colistin resistance trials ([Fig. 6](#f0030){ref-type="fig"}G). These three mutants also \[N103A ([Fig. 6](#f0030){ref-type="fig"}D), T107A ([Fig. 6](#f0030){ref-type="fig"}E) and G322A ([Fig. 6](#f0030){ref-type="fig"}I)\] show a PPEA-1(4′)-lipid A product peak (*m/z*, 1919.585--1920.803), indicating their functionality. Similar results were observed with all 12 mutants during colistin MIC measurements ([Fig. 6](#f0030){ref-type="fig"}H). These *in vivo*in vivo and *in vitro* data give us a mechanistic insight into the importance of cavity-forming residues in the ability of MCR-3 in providing resistance to colistin.

3.7. MCR-3 Quenches Hydroxyl Radical Death Pathway {#s0170}
--------------------------------------------------

Colistin is known to activate a downstream hydroxyl radical mediated cellular death pathway \[[@bb0445], [@bb0500]\]. Recently, the intracellular level of ROS was found to be prevented by the presence of MCR-1/2 and its progenitor ICR-Mo \[[@bb0220]\]. Thereby, we utilized two methods \[chemical rescue assay ([Fig. 8](#f0040){ref-type="fig"}B) and confocal microscopy ([Fig. 8](#f0040){ref-type="fig"}C)\] to evaluate the effect of MCR-3, another lipid A modifier on colistin-induced ROS formation. We show the involvement of the Fenton reaction in the production of free hydroxyl radicals ([Fig. 8](#f0040){ref-type="fig"}A and B) through chemical rescue experiments, where the presence of the ferric chelator bipyridine significantly bypasses the effect of colistin treatment on *mcr-3*-negative *E. coli* ([Fig. 8](#f0040){ref-type="fig"}C)*.* This is also true in the presence of the ROS scavenger, L-cysteine ([Fig. 8](#f0040){ref-type="fig"}C). Surprisingly, *E. coli* is prevented from entering the hydroxy radical death pathway during the expression of *mcr-3* (or *mcr-1/mcr-2*) in the presence of colistin, independent of bipyridine and L-cysteine ([Fig. 8](#f0040){ref-type="fig"}C). To monitor the intracellular production of H~2~O~2~ species in *E. coli* with/without MCR-3 (or MCR-1/MCR-2), an oxidant-susceptible dye DCFH2_DA (2′,7′-dichlorodihydrofluorescein diacetate) was utilized and cells were monitored in a fluorescent field ([Fig. 8](#f0040){ref-type="fig"}D). As expected, treatment with colistin induced ROS production in *E. coli* MG1655 with an empty vector ([Fig. 8](#f0040){ref-type="fig"}D), which was significantly alleviated upon the expression of MCR-3 ([Figs 8](#f0040){ref-type="fig"}E and [9](#f0045){ref-type="fig"}). MCR-3 expression, thus, seems to prevent the entry of colistin into the cells thereby quenching/alleviating ROS production in vivo, and consequently bypassing antibiotic killing by colistin ([Fig. 8](#f0040){ref-type="fig"}B).

3.8. Effects of Intrinsic/Transferable Colistin Resistance Determinants on Metabolic Fitness of Gut Bacteria {#s0175}
------------------------------------------------------------------------------------------------------------

To systematically compare the metabolic fitness of gut bacteria in response of expression of intrinsic and/or transferable colistin resistance determinants, we engineered an array of derivatives of *E. coli* MG1655 \[with the pBAD24 empty vector alone or harboring *eptA*/*mcr*-like gene, in Table S3\]. The five strains used here separately included the negative control FYJ796 (MG1655/pBAD24) \[[@bb0360]\], the neisserial intrinsic colistin resistance gene *eptA*-expressing strain FYJ832 (MG1655/pBAD24*::eptA*) \[[@bb0395]\], and three *mcr-*like gene-bearing strains (FYJ795 \[MG1655/pBAD24*::mcr-1*\] \[[@bb0360]\], FYJ855 \[MG1655/pBAD24*::mcr-2*\] \[[@bb0395]\] & FYJ1125 \[MG1655/pBAD24*::mcr-3*\]). As expected, the following four points are recorded: i) the addition of arabinose (an inducer of the arabinose promoter of pBAD24) failed to exert significant effect on growth curves of MG1655 alone ([Fig. 10](#f0050){ref-type="fig"}A) or with the empty vector pBAD24 ([Fig. 10](#f0050){ref-type="fig"}B); ii) the expression of *eptA* obviously interferes the growth of *E. coli* MG1655 even on the condition of induction with as low as 0.02% arabinose ([Fig. 10](#f0050){ref-type="fig"}C); iii) in general agreement with the observation of *mcr-1* inTOP10 strain \[[@bb0435]\], the expression of MCR-1 (only induced by 0.2% arabinose) can greatly cause growth retardation of the recipient strain MG1655 ([Fig. 10](#f0050){ref-type="fig"}D); iv) the suppressed growth of gut bacterium MG1655 harboring either *mcr-2* ([Fig. 10](#f0050){ref-type="fig"}E) or *mcr-3* ([Fig. 10](#f0050){ref-type="fig"}F) is indistinguishable from that seen with *mcr-1* ([Fig. 10](#f0050){ref-type="fig"}D). Despite that its ability is comparable with that of *eptA* \[[@bb0360]\], BUT weaker than those of *mcr-1/2* in rendering the recipient strain MG1655 resistant to polymyxin \[[@bb0395]\], the cellular effect of *mcr-3* on bacterial growth is surprisingly seen to be similar to those of *mcr-1/2* ([Fig. 10](#f0050){ref-type="fig"}D & E), but somewhat appreciably-less than that of *eptA*, an intrinsic determinant of colistin resistance ([Fig. 10](#f0050){ref-type="fig"}C).

To further address the unexpected scenarios aforementioned amongst MCR-1/2/3 and EptA, we conducted confocal microscopy-based investigation on these gut bacteria using the "LIVE/DEAD" assays of bacterial viability ([Fig. 11](#f0055){ref-type="fig"}). As predicted, low percentage of dead cells was visualized for the log-phase culture of MG1655 carrying pBAD24 ([Fig. 11](#f0055){ref-type="fig"}A and F), whereas appreciably-increased level of killed cells was observed upon the induced expression of EptA with 0.2% arabinose ([Fig. 11](#f0055){ref-type="fig"}B and G). As for every one of *mcr*-like genes ([Fig. 11](#f0055){ref-type="fig"}C--E) in MG1655, activation of its expression apparently produced metabolic pressure featuring with the decrement of bacterial viability ([Fig. 11](#f0055){ref-type="fig"}H-J). In general agreement with scenarios seen in the experiments of growth curves ([Fig. 10](#f0050){ref-type="fig"}), the side effects exerted by MCR-1/2/3 on bacterial viability are consistently less profound than that of EptA ([Fig. 11](#f0055){ref-type="fig"}K), BUT clearly stronger than that of the negative control strain with the empty vector alone ([Fig. 11](#f0055){ref-type="fig"}K). In summary, cellular effects of the three resistance proteins MCR-1/2/3 on bacterial metabolic fitness (at least bacterial growth and viability, if not all) are relatively comparable, despite they are in quite differentiation of gene sequence (Fig. S5) as well as its resultant phenotypic resistance level ([Fig. 4](#f0020){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}).

4. Discussion {#s0180}
=============

More than 11 genetic variants of MCR-3 have been identified since its original discovery in the Shandong province of China. This study has now identified *mcr-3* in bacterial isolates ([Fig. 1](#f0005){ref-type="fig"}) from 8 of the 13 provinces examined in China. This suggests a reasonable level of control in the spread of *mcr-3* within China. This might be indicative of a broader reduction in *mcr* partially caused by the ban of colistin use in animal feedstock in China and by improved animal husbandry practices, though further studies would be necessary. A previous study reported a significantly higher prevalence of *mcr-3* (\>10%) from animals in 9 provinces in China, while the prevalence of *mcr-3* is lower in this study \[[@bb0195]\]. The reasons could attribute to the different sampling time or/and the conditions of antibiotic resistance could be various in different farms.

All four randomly-selected *mcr-3*-positive clinical strains for comparative genomics of *mcr-3*-harboring plasmids also harbored the *mcr-1* gene. In our study, all the three *mcr-3*-positive plasmids were identified through whole genome sequencing to be IncP type conjugable plasmids, while *mcr-1* was on a non-conjugable IncX4-type plasmid. In fact, these 3 plasmids lack the IS*1294* insertion element found on other *mcr-3*-bearing plasmids like pMCR3_ECHEC-LL123 or the IS*Apl1* insertion element found on *mcr-1* plasmids like pMCR_1511. These insertion elements have been proposed to be involved in the initial mobilization of these genes through transposition. It has been shown that *mcr-1* genes lacking insertion elements on either side must have lost them by abortive transposition and without at least a single downstream insertion element incapable of mobilization. Phylogenetically, MCR-3 is very distinct from MCR-1 and its variants ([Fig 3](#f0015){ref-type="fig"}A--B) and clusters within a larger family of MCR-3 like putative PE-lipid A transferases exclusively from the *Aeromonas* species. Interestingly, the neighboring sub-clades consist of putative PE-lipid A transferases from human commensal and naturally colistin-resistant bacteria from *Hafnia* and *Edwardsiella* species. Another neighboring subclade predominantly consists of PE-lipid A transferases from *Vibrio* species where a chromosomal system that attaches glycine to LPS-lipid A GlcN moieties and provides 'intrinsic' resistance to colistin has been described in *Vibrio cholerae*.

Taken together, we can be reasonably confident that MCR-3 and its variants might have a parallel evolutionary path to MCR-1 from a yet to be identified chromosomal progenitor. Despite that the co-occurrence of *mcr-1* and *mcr-3* on certain plasmids \[[@bb0295]\] raises the possibility of *mcr-1/3* evolved through gene duplication events, the poor homology between MCR-1 and MCR-3 argues the aforementioned hypothesis. The divergence of these two groups is probably a distant event and hence, the current source of genetic diversity for each of these species might be different. Recently, *Moraxella* species have been proposed as reservoirs for MCR-1/2 species \[[@bb0215], [@bb0505]\]. A similar reservoir might exist in the Aeromonas ([Fig. 3](#f0015){ref-type="fig"}B), though little is known about the functionality of their MCR-like genes. Unique selection pressures in the environment might have triggered a recent mobilization of some of these intrinsic genes. Z1140 might be an excellent example of a protein caught in the act of evolving either through gain or loss of function over time (Fig. S9). This idea is further strengthened by the biochemical and physiological characterization of MCR-3 which shows that the two distinct protein domains of MCR-1 and MCR-2 are functionally exchangeable, while those in MCR-3 and MCR-1/EptA are not ([Fig. 4](#f0020){ref-type="fig"}). However, we show that MCR-3 and MCR-1/MCR-2/EptA share a common PE substrate binding cavity, which is essential for its activity and for conferring resistance to colistin (Fig. S7). This indicates an evolutionarily conserved mechanism for both intrinsic and transferable polymyxin resistance wherein they share the same catalytic scheme involving a non-sequential or 'ping-pong' reaction mechanism. Further, MCR-3 displays similar abilities in both modifying lipid A structure ([Fig. 5](#f0025){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}) thereby reducing its affinity to colistin. Though polymyxins like colistin have been shown to activate a downstream hydroxyl radical mediated cellular death pathway \[[@bb0445], [@bb0500]\], MCR-3 also quenches ROS production *in vivo* ([Fig. 8](#f0040){ref-type="fig"}) similar to MCR-1/MCR-2/EptA.Fig. 5Enzymology of MCR-3.A. Scheme for the removal of PEA from an alternative substrate NBD-glycerol-3-PEA by MCR-3 to give the product of NBD-glycerol and an intermediate of MCR-3-bound PEA.PEA is an abbreviation of [p]{.ul}hospho[e]{.ul}thanol[a]{.ul}mine. NBD was indicated in blue, and PEA was labelled in red.B. LC/MS determination of the alternative substrate of MCR-3, NBD-glycerol-3-PEA.C. LC/MS-based detection of the NBD-glycerol product from the hydrolysis reaction of the NBD-glycerol-3-PEA substrate by MCR-3.The inside gels denote the TLC assays of the NBD-glycerol-3-PEA substrate (in Panel B) and the MCR-3-catalyzed hydrolysis product, NBD-glycerol (in Panel C). NBD-glycerol-3-PEA is eluted at *m*/*z* of 814.1, whereas the resultant product NBD-glycerol is present at m/z of 691.5.Abbreviation: TLC, thin layer chromatography.D. Schematic illustration for generation of PPEA-4′-lipid A product from lipid A by transferring of PEA from MCR-3-bound PEAMALDI-TOF MS evidence for the chemical modification of the lipid A moieties of lipopolysaccharide (LPS) in GDZJ002, a clinical strain of *mcr-3*-positive *E. coli* strain (E) and its conjugant C600-GDZJ002 (F).The peak of the bis-phosphorylated hexa-acylated lipid A varies at *m/z* (1796.541\~1796.665), whereas resultant derivative with PEA modification (PPEA-4′-lipid A) is at m/z (1919.632\~1919.806).Fig. 5Fig. 6Structure-guided functional dissection of MCR-3 colistin resistance.A. Surface structure of MCR-3 with the cavity required for its PE lipid substrate entry.B. An enlarged illustration for a five residues-containing, Zn^2+^-binding motif.The five residues in Zn^2+^-binding motif of MCR-3 refers to E238, T277, H375, D450 and H451, respectively.C. Surface architecture of MCR-3 in counter-clockwise rotation (30 °).D. An enlarged view of the seven residues-containing motif that is involved in binding of MCR-3 to the PE lipid substrate.The seven residues denote N103, T107, E111, G322, K325, H380 and H463, respectively.E. Western blot analyses of the expression of MCR-3 and its 12 point-mutants in *E. coli.*F. Structure-guided site-directed mutagenesis analyses for the Zn^2+^-binding motif of MCR-3 using the colistin susceptibility assays.G. Functional mapping of the PE-interactive residues of MCR-3 in the context of colistin resistance.H. The measurement of colistin MIC of the *E. coli* strains carrying the wild-type *mcr-3* (and/or its point-mutants).Level of colistin resistance was measured using the LBA plates. A representative result is given from no less than three independent trials.In terms of level of colistin resistance, MCR-3 is almost identical to that of EptA, but only half of that seen with MCR-1.Fig. 6Fig. 7Metabolic evidence that the PE lipid substrate-interactive cavity of MCR-3 participates in chemical modification of the lipid A moieties of lipopolysaccharides in *E. coli.*MALDI-TOF MS spectrum of the LPS-lipid A species isolated from the two negative controls, the *E. coli* strain MG1655 alone (A) and with the empty vector pBAD24 (B).C. Expression of MCR-3 in *E. coli* leads to the appearance of an additional peak of PPEA-4′-lipid A, the modified form of lipid A.The substitution of N103A (D) and T107A (E) in MCR-3 cannot completely impair the enzymatic activity in the structural modification of lipid A moieties.MALDI-TOF MS analyses confirm that the three point-mutants of MCR-3 \[namely E111A (F), E238A (G) and T277A (H)\] are nonfunctional in the transfer of PEA to lipid A species.I. The point mutation of MCR-3 (G322A) does not influence its enzymatic activity in the addition of PPEA to the 4′-phosphate group of lipid A moieties.The six point-mutants of MCR-3 whose enzymatic activities are fully inactivated include K325A (J), H375A (K), H380A (L), D450A (M), H451 (N) and H463A (O), respectively.The MS peak of lipid A species in *E. coli* is shown at m/z of 1796.305--1797.630, whereas its modified form occurs at m/z of 1919.585--1920.803, upon the presence of functional (and/or partial active) versions of *mcr-3* in *E. coli*.Fig. 7Fig. 8A working model for MCR-3-mediated impairment of the hydroxyl radical death pathway in *E. coli.*A. Scheme for membrane disruption by the cationic antimicrobial polypeptide colistin and the resultant ROS production in *E. coli.*B. Functional expression of MCR-3 prevents the penetration of colistin into bacterial membrane and thereafter attenuates the production of ROS in *E. coli.*. It was modified appropriately from Wei et al. \[[@bb0220]\] with permission.C. Chemical rescue experiments reveal that Fenton reaction involves colistin-triggered hydroxyl radical killing pathway in *E. coli.*The LPS-lipid A moiety denotes the first target for colistin treatment. Bipyridine is a well-known ferric chelator, and L-cysteine is the ROS scavenger.D. Exposure to colistin boosts the accumulation of hydrogen peroxides in the negative control, the strain MG1655 of *E. coli* with the empty vector pBAD24.E. The expression of plasmid-borne MCR-3 attenuates the production of hydrogen peroxides in *E. coli*, regardless of the presence of colistin.An oxidant-sensitive dye, DCFH2-DA, was used to detect the level of intracellular ROS, which was oxidized by hydrogen peroxides into the fluorescent product of DCF. The fluorescence intensity of DCF was measured with a Zeiss LSM 510 Meta confocal laser scanning microscope (100× oil immersion objective). Hydrogen peroxides appear in green.F. Quantitative comparison of colistin-promoted ROS levels in *E. coli* with or without expression of *mcr-3.*Ratio of fluorescent cells was calculated through counting the number of cells with/without fluorescence. In each group, no \<500 cells were counted from 4 individual photographs. The data was evaluated through one-way analysis of variance (ANOVA) as well as Tukey--Kramer multiple comparisons post hoc test.Fig. 8Fig. 9Measurement of the quenched ROS levels in *mcr-3*-bearing *E. coli* even with the treatment of colistin.Ratio of fluorescent cells was determined through counting the number of cells with/without fluorescence (seen in [Fig. 8](#f0040){ref-type="fig"}). In total, 500 cells from 4 individual photographs were counted for each group. The data was presented after one-way analysis of variance (ANOVA) along with Tukey--Kramer multiple comparisons post hoc test.Fig. 9Fig. 10Comparison of growth curves of *E. coli* with or without carrying *mcr*-like genes.Growth curves of two negative control strains, the *E. coli* MG1655 alone (A) or carrying the empty vector pBAD24 (B).C. Arabinose-induced expression of the neisserial EptA inhibits the growth of *E. coli* MG1655.D. Expression of MCR-1 exerts effect on the growth of *E. coli* MG1655.E. Expression of MCR-2 interferes the growth of *E. coli* MG1655.F. The presence of MCR-3 inhibits the growth of *E. coli* MG1655.The expression of *eptA* and/or *mcr-1* (*mcr-2* & *mcr-3*) was triggered through the addition of different levels of arabinose (0.00%, 0.02%, and 0.20%, *w*/*v*) into LB media. The means of three independent replicates were shown and the error bars represent the standard deviation (SD).Fig. 10Fig. 11Alteration in bacterial viability of *E. coli* by the expression of *eptA* and/or *mcr*-like genes.Visualization of bacterial viability of the negative control, the empty vector pBAD24-carrying *E. coli* without the addition of arabinose (A) or with the induction of 0.2% arabinose (F).Arabinose-induced expression of *eptA* promotes cell death of *E. coli* (G) when compared with that on the condition lacking arabinose (B).Confocal microscopy-aided detection of LIVE/DEAD biomass of the *E. coli* MG1655 on the growth condition without (C) and with (H) the supplementation of 0.2% arabinose.Visualization of the LIVE/DEAD biomass of the *E. coli* MG1655 expressing *mcr-2* (I) with that of MG1655 without *mcr-2* (D).Comparative analysis of the LIVE/DEAD biomass ratio of the *mcr-3*-harboring *E. coli* MG1655 with (E) or without (J) the induction of 0.2% arabinose.K. Measurement of the relative ratio of LIVE/DEAD *E. coli* strains carrying different colistin resistance determinants.The bacterial cells were incubated with/without 0.2%(*w*/*v*) L-arabinose to trigger the expression of *eptA* (*mcr-1/mcr-2/mcr-3*) and stained with LIVE/DEAD kit, giving the images with Confocal laser scanning microscopy. Green and red separately denotes live and dead cell. \*\*\*, *p* \< .001.Fig. 11

These data together suggest that despite a vast amount of evolutionary diversity in the MCR family, a mechanistic and functional unification is observed. By understanding these aspects of a phylogenetically-distinct member like *mcr-3*, we might be able to track and arrest the origins and spread of colistin resistance. This might also indicate the selection pressures that have resulted in this rapid discovery of *mcr-3* variants across the globe suggesting better policies for antibiotic use in agriculture and medicine. It seems very true that further comprehensive *in vivo* and clinical studies are necessary to understand the threat of *mcr-3* gene to clinical and public health.

The following are the supplementary data related to this article.Fig. S1Genetic analyses for *mcr*-3-carrying plasmids isolated from clinical strainsA. S1-PFGE analyses for clinical *E. coli* strains and their trans-conjugantsB. Southern blotting for clinical *E. coli* strains and their trans-conjugants using *mcr*-3 probeFig. S1Fig. S2Physical map of the *mcr*-3-carrying plasmid pGDZJ002-1Circles (from inside to outside) represent the GC screw, GC content and ORF, respectively \[[@bb0135]\]. The plasmid genomes are annotated by RAST. The plasmid maps are generated with Circos program \[[@bb0135]\].Fig. S2Fig. S3Genomic map of the *mcr*-3-harboring plasmid pGDZJ004Fig. S3Fig. S4Colinear genome analyses of four *mcr*-3-bearing plasmids.Boxed arrows represent the position and transcriptional direction of the ORFs. Regions of \>99% identity are given by grey shading. The antibiotic resistance gene *mcr*-3 and its variant *mcr*-3.7 are colored in blue.Fig. S4Fig. S5Bioinformatic analyses of MCR-3.A. Transmembrane prediction of MCR-3B. Sequence alignment of MCR-3 with EptA and MCR-1/2 homologs.Fig. S5Fig. S6Characterization of MCR-3 protein.A. Western blot detection suggests sub-cellular localization of MCR-3 in the membrane-associated fraction from E. coli lysates Designations： L, Lysate of *E. coli* following sonication; S, Supernatant of bacterial crude extracts undergoing ultra-centrifugation; P, Pellet of bacterial crude extracts undergoing ultra-centrifugation; D, Detergent-solubilized fraction. B. SDS-PAGE (15%) profile of the purified MCR-3 C. Use of MALDI-TOF to determine the molecular mass of MCR-3 The mass of MCR-3 is unveiled to be 61.3 kDa. D. MS identification of the recombinant MCR-3 integral membrane protein. The transmembrane region of MCR-3 is in light blue, and the enzymatic domain is in red. The polypeptides that have been identified by MS and match MCR-3 are underlined with coverage of 56.4%. E. Circular dichroism (CD)-based illustration of the protein secondary structure of MCR-3. F. Use of ICP/MS to determine the existence of MCR-3 in the zinc-bound form G. Overall architecture of the modelled MCR-3 structure. Abbreviations: C, C-terminus; N, N-terminus.Fig. S6Fig. S7Parallels in PE-recognizing cavities of MCR-like enzymes.A. Enlarged view of surface structure of EptA having a cavity for the entry of PE lipid substrate B. Structural snapshot of the PE lipid substrate-interactive cavity in MCR-1. C. A similar PE-recognizing cavity is present in MCR-2. D. A conservative PE-binding cavity is also shared by MCR-3. The enlarged surface structures of PE-binding cavities are generated through molecular docking together with structural modelling. The PE molecules are denoted with green sticks, and cavity is indicated with an arrow. The photographs are generated using PyMol. Designations: PE: phosphatidylethanolamine.Fig. S7Fig. S8Structural similarity of PE-recognizing cavities of MCR-like enzymes.A. A putative Zn2+-centering, five-residues forming motif is conserved amongst PE lipid substrate-recognizing cavities of four MCR-like paralogues EptA, MCR-1, MCR-2 and MCR-3. B. Comparative analyses of the conserved PE-recognizable residues of four MCR-like enzymes EptA, MCR-1, MCR-2 and MCR-3 With an exception that the conserved serine (S325 in EptA, S330 in MCR-1 and S328 in MCR-2) is replaced with glycine on the residue 322 (G322) in MCR-3, all the other six residues are identical in these cavities. The photographs are produced with PyMol.Fig. S8Fig. S9Both the *E. coli* O157: H7 strain EDL933 and the E. coli MG1655 strain carrying Z1140 (a putative PEA lipid A transferase from Strain EDL933) are susceptible to colistin, whereas the expression of *mcr*-3 (and its hybrid version of TMZ-MCR-3) confers the recipient strain MG1655 resistant to colistinThe mid-log phase cultures (in serial dilution) were spotted on LBA plates containing varied levels of colistin (0, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0 and 32.0 11 μg/ml) and kept overnight at 37°C. Plasmid-borne expression of mcr-3 (TMZ-MCR-3) is induced with the addition of 0.2% arabinose. Designations: Vec, the empty vector pBAD24; TMZ-MCR-3, a hybrid version of MCR-3 in which the TM region is replaced with the counterpart in Z1140 of the E. coli O157:H7 strain EDL933. A representative result of three independent experiments is given.Fig. S9Supplementary material 1Image 1Supplementary material 2Image 2Supplementary material 3Image 3Supplementary material 4Image 4
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